Epigenomic analysis of Parkinson's disease neurons identifies Tet2 loss as neuroprotective.


Journal

Nature neuroscience
ISSN: 1546-1726
Titre abrégé: Nat Neurosci
Pays: United States
ID NLM: 9809671

Informations de publication

Date de publication:
10 2020
Historique:
received: 16 09 2019
accepted: 07 07 2020
pubmed: 19 8 2020
medline: 15 12 2020
entrez: 19 8 2020
Statut: ppublish

Résumé

Parkinson's disease (PD) pathogenesis may involve the epigenetic control of enhancers that modify neuronal functions. Here, we comprehensively examine DNA methylation at enhancers, genome-wide, in neurons of patients with PD and of control individuals. We find a widespread increase in cytosine modifications at enhancers in PD neurons, which is partly explained by elevated hydroxymethylation levels. In particular, patients with PD exhibit an epigenetic and transcriptional upregulation of TET2, a master-regulator of cytosine modification status. TET2 depletion in a neuronal cell model results in cytosine modification changes that are reciprocal to those observed in PD neurons. Moreover, Tet2 inactivation in mice fully prevents nigral dopaminergic neuronal loss induced by previous inflammation. Tet2 loss also attenuates transcriptional immune responses to an inflammatory trigger. Thus, widespread epigenetic dysregulation of enhancers in PD neurons may, in part, be mediated by increased TET2 expression. Decreased Tet2 activity is neuroprotective, in vivo, and may be a new therapeutic target for PD.

Identifiants

pubmed: 32807949
doi: 10.1038/s41593-020-0690-y
pii: 10.1038/s41593-020-0690-y
doi:

Substances chimiques

DNA-Binding Proteins 0
Proto-Oncogene Proteins 0
Dioxygenases EC 1.13.11.-
TET2 protein, human EC 1.13.11.-
Tet2 protein, mouse EC 1.13.11.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1203-1214

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS114409
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939–953 (2018).
doi: 10.1016/S1474-4422(18)30295-3
Wirdefeldt, K., Gatz, M., Reynolds, C. A., Prescott, C. A. & Pedersen, N. L. Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol. Aging 32, 1923.e1–1923.e8 (2011).
doi: 10.1016/j.neurobiolaging.2011.02.017
Gomez-Esteban, J. C. et al. Factors influencing the symmetry of Parkinson’s disease symptoms. Clin. Neurol. Neurosurg. 112, 302–305 (2010).
pubmed: 20083340 doi: 10.1016/j.clineuro.2009.12.017 pmcid: 20083340
Baldereschi, M. et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55, 1358–1363 (2000).
pubmed: 11087781 doi: 10.1212/WNL.55.9.1358 pmcid: 11087781
Labbe, C., Lorenzo-Betancor, O. & Ross, O. A. Epigenetic regulation in Parkinson’s disease. Acta Neuropathol. 132, 515–530 (2016).
pubmed: 27358065 pmcid: 5026906 doi: 10.1007/s00401-016-1590-9
Jakubowski, J. L. & Labrie, V. Epigenetic biomarkers for Parkinson’s disease: from diagnostics to therapeutics. J. Parkinsons Dis. 7, 1–12 (2017).
pubmed: 27792016 pmcid: 5302044 doi: 10.3233/JPD-160914
Masliah, E., Dumaop, W., Galasko, D. & Desplats, P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 8, 1030–1038 (2013).
pubmed: 23907097 pmcid: 3891683 doi: 10.4161/epi.25865
Kaut, O., Schmitt, I. & Wullner, U. Genome-scale methylation analysis of Parkinson’s disease patients’ brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 13, 87–91 (2012).
pubmed: 22238121 doi: 10.1007/s10048-011-0308-3 pmcid: 22238121
Young, J. I. et al. Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease. Neurol. Genet. 5, e342 (2019).
pubmed: 31403079 pmcid: 6659138 doi: 10.1212/NXG.0000000000000342
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211 (2003).
doi: 10.1016/S0197-4580(02)00065-9
Guo, J. U. et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat. Neurosci. 14, 1345–1351 (2011).
pubmed: 21874013 pmcid: 3183401 doi: 10.1038/nn.2900
Feng, J. et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci. 13, 423–430 (2010).
pubmed: 20228804 pmcid: 3060772 doi: 10.1038/nn.2514
Li, X. et al. Ten-eleven translocation 2 interacts with forkhead box O3 and regulates adult neurogenesis. Nat. Commun. 8, 15903 (2017).
pubmed: 28660881 pmcid: 5493768 doi: 10.1038/ncomms15903
Hon, G. C. et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol. Cell 56, 286–297 (2014).
pubmed: 25263596 pmcid: 25263596 doi: 10.1016/j.molcel.2014.08.026
Lister, R. et al. Global epigenomic reconfiguration during mammalian brain development. Science 341, 1237905 (2013).
pubmed: 23828890 pmcid: 3785061 doi: 10.1126/science.1237905
Price, A. J. et al. Divergent neuronal DNA methylation patterns across human cortical development reveal critical periods and a unique role of CpH methylation. Genome Biol. 20, 196 (2019).
pubmed: 31554518 pmcid: 6761727 doi: 10.1186/s13059-019-1805-1
Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
Dao, L. T. M. et al. Genome-wide characterization of mammalian promoters with distal enhancer functions. Nat. Genet. 49, 1073–1081 (2017).
pubmed: 28581502 doi: 10.1038/ng.3884 pmcid: 28581502
Dong, X. et al. Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease. Nat. Neurosci. 21, 1482–1492 (2018).
pubmed: 30224808 pmcid: 6334654 doi: 10.1038/s41593-018-0223-0
Soldner, F. et al. Parkinson-associated risk variant in distal enhancer of ɑ-synuclein modulates target gene expression. Nature 533, 95–99 (2016).
pubmed: 27096366 pmcid: 27096366 doi: 10.1038/nature17939
Fernandez-Santiago, R. et al. Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson’s disease patients. EMBO Mol. Med. 7, 1529–1546 (2015).
pubmed: 26516212 pmcid: 4693505 doi: 10.15252/emmm.201505439
Li, P. et al. Hemispheric asymmetry in the human brain and in Parkinson’s disease is linked to divergent epigenetic patterns in neurons. Genome Biol. 21, 61 (2020).
pubmed: 32151270 pmcid: 7063821 doi: 10.1186/s13059-020-01960-1
Narayanan, N. S., Rodnitzky, R. L. & Uc, E. Y. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev. Neurosci. 24, 267–278 (2013).
pubmed: 23729617 doi: 10.1515/revneuro-2013-0004 pmcid: 23729617
Luo, C. et al. Single-cell methylomes identify neuronal subtypes and regulatory elements in mammalian cortex. Science 357, 600–604 (2017).
pubmed: 28798132 pmcid: 5570439 doi: 10.1126/science.aan3351
Farley, J. E. et al. Transcription factor Pebbled/RREB1 regulates injury-induced axon degeneration. Proc. Natl Acad. Sci. USA 115, 1358–1363 (2018).
pubmed: 29295933 doi: 10.1073/pnas.1715837115 pmcid: 29295933
Schmitt, A. D. et al. A compendium of chromatin contact maps reveals spatially active regions in the human genome. Cell Rep. 17, 2042–2059 (2016).
pubmed: 27851967 pmcid: 5478386 doi: 10.1016/j.celrep.2016.10.061
Lio, C. J. & Rao, A. TET enzymes and 5hmC in adaptive and innate immune systems. Front. Immunol. 10, 210 (2019).
pubmed: 30809228 pmcid: 6379312 doi: 10.3389/fimmu.2019.00210
Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102 (2019).
doi: 10.1016/S1474-4422(19)30320-5 pubmed: 31701892
Figge, D. A., Eskow Jaunarajs, K. L. & Standaert, D. G. Dynamic DNA methylation regulates levodopa-induced dyskinesia. J. Neurosci. 36, 6514–6524 (2016).
pubmed: 27307239 pmcid: 5015786 doi: 10.1523/JNEUROSCI.0683-16.2016
Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 32, 896–902 (2014).
pubmed: 4404308 pmcid: 4404308 doi: 10.1038/nbt.2931
Donega, V. et al. Transcriptome and proteome profiling of neural stem cells from the human subventricular zone in Parkinson’s disease. Acta Neuropathol. Commun. 7, 84 (2019).
pubmed: 31159890 doi: 10.1186/s40478-019-0736-0 pmcid: 31159890
Johnson, M. E., Stecher, B., Labrie, V., Brundin, L. & Brundin, P. Triggers, facilitators, and aggravators: redefining Parkinson’s disease pathogenesis. Trends Neurosci. 42, 4–13 (2019).
pubmed: 30342839 doi: 10.1016/j.tins.2018.09.007 pmcid: 30342839
Qin, L. et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55, 453–462 (2007).
pubmed: 17203472 pmcid: 2871685 doi: 10.1002/glia.20467
Brichta, L. et al. Identification of neurodegenerative factors using translatome-regulatory network analysis. Nat. Neurosci. 18, 1325–1333 (2015).
pubmed: 26214373 pmcid: 4763340 doi: 10.1038/nn.4070
Sodersten, E. et al. A comprehensive map coupling histone modifications with gene regulation in adult dopaminergic and serotonergic neurons. Nat. Commun. 9, 1226 (2018).
pubmed: 29581424 pmcid: 5964330 doi: 10.1038/s41467-018-03538-9
Wu, T. T. et al. TET2-mediated Cdkn2A DNA hydroxymethylation in midbrain dopaminergic neuron injury of Parkinson’s disease. Hum. Mol. Genet. 29, 1239–1252 (2020).
pubmed: 32037456 doi: 10.1093/hmg/ddaa022 pmcid: 32037456
Kriaucionis, S. & Heintz, N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929–930 (2009).
pubmed: 3263819 pmcid: 3263819 doi: 10.1126/science.1169786
Kozlenkov, A. et al. A unique role for DNA (hydroxy)methylation in epigenetic regulation of human inhibitory neurons. Sci. Adv. 4, eaau6190 (2018).
pubmed: 30263963 pmcid: 6157969 doi: 10.1126/sciadv.aau6190
Szulwach, K. E. et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14, 1607–1616 (2011).
pubmed: 22037496 pmcid: 3292193 doi: 10.1038/nn.2959
Herrup, K. & Yang, Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat. Rev. Neurosci. 8, 368–378 (2007).
pubmed: 17453017 doi: 10.1038/nrn2124 pmcid: 17453017
Ellison, E. M., Abner, E. L. & Lovell, M. A. Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer’s disease. J. Neurochem. 140, 383–394 (2017).
pubmed: 27889911 pmcid: 5250541 doi: 10.1111/jnc.13912
Stoger, R., Scaife, P. J., Shephard, F. & Chakrabarti, L. Elevated 5hmC levels characterize DNA of the cerebellum in Parkinson’s disease. NPJ Parkinsons Dis. 3, 6 (2017).
pubmed: 28649606 pmcid: 5460211 doi: 10.1038/s41531-017-0007-3
Carrillo-Jimenez, A. et al. TET2 regulates the neuroinflammatory response in microglia. Cell Rep. 29, e698 (2019).
doi: 10.1016/j.celrep.2019.09.013
Jain, N. et al. Global modulation in DNA epigenetics during pro-inflammatory macrophage activation. Epigenetics 14, 1183–1193 (2019).
pubmed: 31262215 pmcid: 6791700 doi: 10.1080/15592294.2019.1638700
Zhang, Q. et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393 (2015).
pubmed: 26287468 pmcid: 4697747 doi: 10.1038/nature15252
Pronier, E. et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118, 2551–2555 (2011).
pubmed: 21734233 pmcid: 3292425 doi: 10.1182/blood-2010-12-324707
Ichiyama, K. et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 42, 613–626 (2015).
pubmed: 25862091 pmcid: 4956728 doi: 10.1016/j.immuni.2015.03.005
Izzo, F. et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat. Genet. 52, 378–387 (2020).
pubmed: 32203468 pmcid: 7216752 doi: 10.1038/s41588-020-0595-4
Gagne, J. J. & Power, M. C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74, 995–1002 (2010).
pubmed: 20308684 pmcid: 2848103 doi: 10.1212/WNL.0b013e3181d5a4a3
Peter, I. et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 75, 939–946 (2018).
pubmed: 29710331 pmcid: 6142934 doi: 10.1001/jamaneurol.2018.0605
Caligiore, D. et al. Parkinson’s disease as a system-level disorder. NPJ Parkinsons Dis. 2, 16025 (2016).
pubmed: 28725705 pmcid: 5516580 doi: 10.1038/npjparkd.2016.25
Weintraub, D. et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch. Neurol. 68, 1562–1568 (2011).
pubmed: 22159053 pmcid: 3290902 doi: 10.1001/archneurol.2011.725
Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136, 2419–2431 (2013).
pubmed: 23884810 pmcid: 3722357 doi: 10.1093/brain/awt192
Li, P. et al. Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms. Nat. Commun. 10, 2246 (2019).
pubmed: 31113950 pmcid: 6529540 doi: 10.1038/s41467-019-10101-7
Pai, S. et al. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat. Commun. 10, 2046 (2019).
pubmed: 31053723 pmcid: 6499808 doi: 10.1038/s41467-019-09786-7
He, Y. & Wang, T. EpiCompare: an online tool to define and explore genomic regions with tissue or cell type-specific epigenomic features. Bioinformatics 33, 3268–3275 (2017).
pubmed: 28605501 pmcid: 5860030 doi: 10.1093/bioinformatics/btx371
Ernst, J. & Kellis, M. Chromatin-state discovery and genome annotation with ChromHMM. Nat. Protoc. 12, 2478–2492 (2017).
pubmed: 29120462 pmcid: 5945550 doi: 10.1038/nprot.2017.124
Labrie, V. et al. Lactase nonpersistence is directed by DNA-variation-dependent epigenetic aging. Nat. Struct. Mol. Biol. 23, 566–573 (2016).
pubmed: 27159559 pmcid: 4899171 doi: 10.1038/nsmb.3227
Diep, D. et al. Library-free methylation sequencing with bisulfite padlock probes. Nat. Methods 9, 270–272 (2012).
pubmed: 22306810 pmcid: 3461232 doi: 10.1038/nmeth.1871
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-seq applications. Bioinformatics 27, 1571–1572 (2011).
pubmed: 21493656 pmcid: 3102221 doi: 10.1093/bioinformatics/btr167
The 1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
pmcid: 4750478 doi: 10.1038/nature15393
Mo, A. et al. Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron 86, 1369–1384 (2015).
pubmed: 26087164 pmcid: 4499463 doi: 10.1016/j.neuron.2015.05.018
Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243–259 (2018).
pubmed: 29344893 pmcid: 29344893 doi: 10.1007/978-1-4939-7493-1_12
Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
pubmed: 3491415 pmcid: 3491415 doi: 10.1186/gb-2012-13-10-r87
Kwon, A. T., Arenillas, D. J., Worsley Hunt, R. & Wasserman, W. W. oPOSSUM-3: advanced analysis of regulatory motif over-representation across genes or ChIP-seq datasets. G3 (Bethesda) 2, 987–1002 (2012).
doi: 10.1534/g3.112.003202
Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 159, 1665–1680 (2014).
pubmed: 25497547 pmcid: 25497547 doi: 10.1016/j.cell.2014.11.021
Mishra, A. & Hawkins, R. D. Three-dimensional genome architecture and emerging technologies: looping in disease. Genome Med. 9, 87 (2017).
pubmed: 28964259 pmcid: 5623062 doi: 10.1186/s13073-017-0477-2
Wingett, S. et al. HiCUP: pipeline for mapping and processing Hi-C data. F1000Res. 4, 1310 (2015).
pubmed: 26835000 pmcid: 4706059 doi: 10.12688/f1000research.7334.1
Forcato, M. et al. Comparison of computational methods for Hi-C data analysis. Nat. Methods 14, 679–685 (2017).
pubmed: 28604721 pmcid: 5493985 doi: 10.1038/nmeth.4325
Levy-Leduc, C., Delattre, M., Mary-Huard, T. & Robin, S. Two-dimensional segmentation for analyzing Hi-C data. Bioinformatics 30, i386–i392 (2014).
pubmed: 25161224 pmcid: 4147896 doi: 10.1093/bioinformatics/btu443
McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010).
pubmed: 20436461 pmcid: 4840234 doi: 10.1038/nbt.1630
Reimand, J., Kull, M., Peterson, H., Hansen, J. & Vilo, J. g:Profiler—a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 35, W193–W200 (2007).
pubmed: 17478515 pmcid: 1933153 doi: 10.1093/nar/gkm226
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 doi: 10.1073/pnas.0506580102 pmcid: 16199517
Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 14, 482–517 (2019).
pubmed: 30664679 pmcid: 6607905 doi: 10.1038/s41596-018-0103-9
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
pubmed: 3322381 pmcid: 3322381 doi: 10.1038/nmeth.1923
Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187–W191 (2014).
pubmed: 24799436 pmcid: 4086134 doi: 10.1093/nar/gku365
Diaz, A., Park, K., Lim, D. A. & Song, J. S. Normalization, bias correction, and peak calling for ChIP-seq. Stat. Appl. Genet. Mol. Biol. 11, 9 (2012).
doi: 10.1515/1544-6115.1750
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982 pmcid: 2592715 doi: 10.1186/gb-2008-9-9-r137
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
doi: 10.1093/bioinformatics/btp616 pubmed: 19910308
Yu, Q. & He, Z. Comprehensive investigation of temporal and autism-associated cell type composition-dependent and independent gene expression changes in human brains. Sci. Rep. 7, 4121 (2017).
pubmed: 28646201 pmcid: 5482876 doi: 10.1038/s41598-017-04356-7
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 4402510 pmcid: 4402510 doi: 10.1093/nar/gkv007
Konnova, E. A. & Swanberg, M. Animal models of Parkinson’s disease. in Parkinson’s Disease: Pathogenesis and Clinical Aspects (eds Stoker, T. B. & Greenland, J. C.) (Codon Publications, 2018).
Caiazzo, M. et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224–227 (2011).
pubmed: 21725324 doi: 10.1038/nature10284 pmcid: 21725324
Cheng, L. et al. Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm). Sci. Rep. 6, 22398 (2016).
pubmed: 26928495 pmcid: 4772163 doi: 10.1038/srep22398
Chen, X. et al. Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc. Natl Acad. Sci. USA 116, 5765–5774 (2019).
pubmed: 30842285 doi: 10.1073/pnas.1814909116 pmcid: 30842285
Maco, B. et al. Semiautomated correlative 3D electron microscopy of in vivo-imaged axons and dendrites. Nat. Protoc. 9, 1354–1366 (2014).
pubmed: 24833174 doi: 10.1038/nprot.2014.101 pmcid: 24833174
McQuin, C. et al. CellProfiler 3.0: next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).
pubmed: 29969450 pmcid: 6029841 doi: 10.1371/journal.pbio.2005970

Auteurs

Lee L Marshall (LL)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Bryan A Killinger (BA)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.
Department of Neurological Sciences, Rush Medical Center, Chicago, IL, USA.

Elizabeth Ensink (E)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Peipei Li (P)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Katie X Li (KX)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Wei Cui (W)

Center for Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.

Noah Lubben (N)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Matthew Weiland (M)

Center for Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
DeVos Cardiovascular Research Program Van Andel Institute-Spectrum Health, Grand Rapids, MI, USA.

Xinhe Wang (X)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Juozas Gordevicius (J)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.
Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Gerhard A Coetzee (GA)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Jiyan Ma (J)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.

Stefan Jovinge (S)

Center for Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.
DeVos Cardiovascular Research Program Van Andel Institute-Spectrum Health, Grand Rapids, MI, USA.
Cardiovascular Institute, Stanford University, Palo Alto, CA, USA.

Viviane Labrie (V)

Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA. viviane.labrie@vai.org.
Division of Psychiatry and Behavioral Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. viviane.labrie@vai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH